{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0000557\nAge: 82\nGender: Male\nSample ID: P-0000557-T01-IM3\nGene Panel: IMPACT341\nCancer Type: Lung Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 70.0%\n=============\nDNA Variants:\nTP53 c.724T>G (p.C242G) - in 13.00% of 198 reads\nCNA Data:\nNo CNA data found.\nStructural Variants:\nALK - EML4 (INVERSION)\n    \n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n    \"Disease Phase or Condition\": \"Metastatic NSCLC with no EGFR or ALK genomic tumor aberrations\",\n    \"Drug Name\": \"Cisplatin + Durvalumab + Tremelimumab + Pemetrexed\",\n    \"Prior Treatment or Resistance Status\": \"No prior treatment specified; treatment approved for first-line setting\",\n    \"Genomic Features\": \"Wild type ALK, Wild type EGFR\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n    \"Disease Phase or Condition\": \"Metastatic NSCLC with no EGFR or ALK genomic tumor aberrations\",\n    \"Drug Name\": \"Carboplatin + Durvalumab + Tremelimumab + Pemetrexed\",\n    \"Prior Treatment or Resistance Status\": \"No prior treatment specified; treatment approved for first-line setting\",\n    \"Genomic Features\": \"Wild type ALK, Wild type EGFR\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf\"\n  },\n  \"Treatment 3\": {\n    \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n    \"Disease Phase or Condition\": \"Metastatic NSCLC with no EGFR or ALK genomic tumor aberrations\",\n    \"Drug Name\": \"Gemcitabine + Cisplatin or Carboplatin + Durvalumab + Tremelimumab\",\n    \"Prior Treatment or Resistance Status\": \"No prior treatment specified; treatment approved for first-line setting\",\n    \"Genomic Features\": \"Wild type ALK, Wild type EGFR\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf\"\n  },\n  \"Treatment 4\": {\n    \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n    \"Disease Phase or Condition\": \"Metastatic NSCLC with no EGFR or ALK genomic tumor aberrations\",\n    \"Drug Name\": \"Nab-paclitaxel + Carboplatin + Durvalumab + Tremelimumab\",\n    \"Prior Treatment or Resistance Status\": \"No prior treatment specified; treatment approved for first-line setting\",\n    \"Genomic Features\": \"Wild type ALK, Wild type EGFR\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf\"\n  },\n  \"Treatment 5\": {\n    \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n    \"Disease Phase or Condition\": \"Metastatic NSCLC with no EGFR or ALK genomic tumor aberrations\",\n    \"Drug Name\": \"Pembrolizumab in combination with Pemetrexed and Platinum Chemotherapy\",\n    \"Prior Treatment or Resistance Status\": \"First-line treatment for metastatic non-squamous NSCLC\",\n    \"Genomic Features\": \"Wild type ALK, Wild type EGFR\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\"\n  },\n  \"Treatment 6\": {\n    \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n    \"Disease Phase or Condition\": \"Metastatic NSCLC with no EGFR or ALK genomic tumor aberrations\",\n    \"Drug Name\": \"Pembrolizumab in combination with Pemetrexed and Platinum Chemotherapy\",\n    \"Prior Treatment or Resistance Status\": \"First-line treatment for metastatic non-squamous NSCLC\",\n    \"Genomic Features\": \"Wild type ALK, Wild type EGFR\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf\"\n  },\n  \"Treatment 7\": {\n    \"Disease Name\": \"Non-Small Cell Lung Cancer (NSCLC)\",\n    \"Disease Phase or Condition\": \"Metastatic NSCLC with no EGFR or ALK genomic tumor aberrations\",\n    \"Drug Name\": \"Ipilimumab + Nivolumab + 2 cycles of platinum-doublet chemotherapy\",\n    \"Prior Treatment or Resistance Status\": \"For metastatic or recurrent NSCLC, first-line setting\",\n    \"Genomic Features\": \"Wild type ALK, Wild type EGFR\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf\"\n  }\n}"
}